Sec Form 13G Filing - Schemel Donald Robert filing for Panbela Therapeutics Inc. (PBLA) - 2020-02-14

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 3)*

 

 

Sun BioPharma, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
	86664M107
	(CUSIP Number)
	December 31, 2019
	(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

	☐	Rule 13d-1(b)
	☒	Rule 13d-1(c)
	☐	Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

  

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

Page 1 of 5

 

CUSIP No. 86664M107

13G

 

1	names of reporting persons I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
	D. Robert Schemel
2	check the appropriate box if a member of a group*			(a) ☐ (b) ☐
3	sec use only
4	citizenship or place of organization
	USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	sole voting power
			125,395(1)
		6	shared voting power
			282,654
		7	sole dispositive power
			125,395(1)
		8	shared dispositive power
			282,654
9	aggregate amount beneficially owned by each reporting person
	408,049 SHARES(1)
10	check if the aggregate amount in row (9) excludes certain shares*			☐
11	percent of class represented by amount in row (9)
	6.2%
12	type of reporting person*
	IN
(1) This includes 24,200 stock options and warrants to purchase 11,767 shares of common stock.

 

*SEE INSTRUCTION BEFORE FILLING OUT!

 

Page 2 of 5

Item 1.
	(a)	Name of Issuer
		Sun BioPharma, Inc.
	(b)	Address of Issuer’s Principal Executive Offices
		712 Vista Blvd., #305
		Waconia, MN 55387

 

Item 2.
	(a)	Name of Person Filing
		D. Robert Schemel
	(b)	Address of Principal Business Office or, if none, Residence
		712 Vista Blvd., #305
		Waconia, MN 55387
	(c)	Citizenship
		USA
	(d)	Title of Class of Securities
		Common Stock
	(e)	CUSIP Number
		86664M107

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check  whether the person filing is a:

 

	(a)	☐	Broker or dealer registered under Section 15 of the Act.
	(b)	☐	Bank as defined in Section 3(a)(6) of the Act.
	(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act.
	(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940.
	(e)	☐	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
	(f)	☐	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
	(g)	☐	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
	(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
	(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
	(j)	☐	Group, in accordance with § 240.13d-1(b)(1)(ii)(J).

 

Page 3 of 5

Item 4.	Ownership
	(a)	Amount Beneficially Owned
		408,049 Shares
	(b)	Percent of Class
		6.2%
	(c)	Number of shares as to which such person has:
		(i)	Sole power to vote or to direct the vote
			125,395
		(ii)	Shared power to vote or to direct the vote
			282,654
		(iii)	Sole power to dispose or to direct the disposition of
			125,395
		(iv)	Shared power to dispose or to direct the disposition of
			282,654

 

Item 5.		Ownership of Five Percent or Less of a Class:
		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6.		Ownership of More than Five Percent on Behalf of Another Person:
		Not Applicable.
Item 7.		Identification and Classification of the Subsidiary Which Acquired the
		Security Being Reported on by the Parent Holding Company or Control Person:
		Not Applicable.
Item 8.		Identification and Classification of Members of the Group:
		Not Applicable.
Item 9.		Notice of Dissolution of Group:
		Not Applicable.

 

 

Page 4 of 5

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

	February 14, 2020
	Date
	/s/ D. Robert Schemel
	Signature
	/s/ D. Robert Schemel
	Name/Title

 

 

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties for whom copies are to be sent.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

 

Page 5 of 5